Sirion Biotech, Sanofi to improve AAV capsids

By The Science Advisory Board staff writers

February 23, 2021 -- Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors for the development of effective gene therapies.

The companies, along with AAV biology scientist Dirk Grimm, PhD, of Heidelberg University Hospital, will combine proprietary technology platforms to create next generation AAV vectors. The goal of the collaboration is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency.

Sanofi will leverage its expertise in virus-based vaccine and viral vector manufacturing, while Grimm will contribute AAV capsid evolution technology. Sirion will provide capabilities in AAV vector manufacturing.

Financial details of the collaboration were not disclosed.

Sanofi, GSK start phase II COVID-19 vaccine study
Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.
Curadigm collaborates with Sanofi on combo product to improve gene therapies
Nanobiotix, through its wholly owned subsidiary Curadigm, has signed a new collaboration agreement with Sanofi for the use of its Nanoprimer technology...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter